Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today

At present, the hormone EPO is administered to a large number of these patients to alleviate the anemia. But unfortunately, treatment with EPO is not always effective, and not all patients respond to this therapy. VIB scientists connected to the Katholieke Universiteit Leuven have been researching the role of the Gas6 protein. This substance has proven successful in the treatment of mice with anemia, without causing the side effects that the use of EPO entails. In addition, Gas6 contributes to a reinforcement of EPO’s effect. Gas6 might possibly form the basis for a new treatment for anemia and offer a remedy for patients where EPO is ineffective.

What is anemia?

When the blood contains too few red blood cells, or when the red blood cells contain too little hemoglobin, the condition is called anemia. Hemoglobin binds to oxygen from the lungs and conveys it throughout our bodies, where it plays an essential role in the body’s production of energy. If there are not enough red blood cells in our body, or if the red blood cells do not contain enough hemoglobin, then insufficient oxygen is transported. A shortage of oxygen in our tissues can cause people to feel tired and weak, and serious cardiovascular, neurological and musculoskeletal abnormalities develop.

EPO as the remedy

EPO (or Erythropoietin) is a hormone that is produced predominantly in the kidneys and that stimulates the formation of red blood cells. However, sometimes the kidneys do not produce enough EPO and anemia results. Such a shortage of EPO often occurs in patients with a chronic disorder (like kidney failure or rheumatoid arthritis) and in cancer patients. In the case of cancer, anemia can be caused by the disease itself as well as by chemotherapy.

When patients with chronic kidney ailments or cancer develop anemia, the human EPO protein is produced in mammalian cells and administered as a drug. The EPO then stimulates the formation of red blood cells, thus alleviating the anemia. But, in a large number of patients, the use of EPO as a remedy fails; in some patients, even high dosages of EPO are not effective.

Gas6 as alternative – and safer – remedy?

VIB researcher Diether Lambrechts and his colleagues have been studying – under the direction of Ed Conway and Peter Carmeliet, and in collaboration with foreign experts – the role of the Gas6 protein in mice. While EPO plays a prominent role in the production of red blood cells throughout our life, Gas6 is only involved in the production of red blood cells in adulthood.

When mice with anemia are treated with Gas6, the red blood cells once again rise to their normal levels in the blood. In contrast to EPO, the use of Gas6 does not result in an excessive production of red blood cells, which increases the risk of thrombosis. Furthermore, Gas6 reinforces the effect of EPO: indeed, when Gas6 is administered to mice that have not produced enough EPO, it works just as well as EPO, and a combined treatment of Gas6 and EPO produces an even greater therapeutic effect.

So, the positive evaluation of Gas6 in anemic mice raises hopes for a more effective and safer remedy for chronic disease patients who have to contend with anemia as a consequence of their disease or therapy.

Media Contact

Ann Van Gysel alfa

More Information:

http://www.vib.be

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Perovskite solar cells soar to new heights

Metal halide perovskites have been under intense investigation over the last decade, due to the remarkable rise in their performance in optoelectronic devices such as solar cells or light-emitting diodes….

Blue hydrogen can help protect the climate

An international group of researchers led by the Paul Scherrer Institute and the Heriot-Watt University has carried out in-depth analyses of the climate impact of blue hydrogen. This is produced…

Genes associated with hearing loss visualised in new study

Researchers from Uppsala University have been able to document and visualise hearing loss-associated genes in the human inner ear, in a unique collaboration study between otosurgeons and geneticists. The findings…

Partners & Sponsors